4.5 Review

NEDA treatment target? No evident disease activity as an actionable outcome in practice

期刊

JOURNAL OF THE NEUROLOGICAL SCIENCES
卷 383, 期 -, 页码 31-34

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jns.2017.10.015

关键词

No evident disease activity; Multiple sclerosis; Disease modifying therapy; Outcome measures; Treatment target

资金

  1. Sanofi
  2. Novartis
  3. Biogen Pharmaceuticals
  4. National Multiple Sclerosis Foundation
  5. Alexion
  6. TerumoBCT

向作者/读者索取更多资源

No evident disease activity (NEDA) is a proposed measure of disease activity-free status in multiple sclerosis (MS) that is typically defined as absence of relapses, disability progression, and MRI activity over a defined time period. NEDA is increasingly reported in randomized controlled trials of MS disease modifying therapies where it has some perceived advantages over outcomes such as annualized relapse rate. NEDA has also been proposed as a treatment goal in clinical care. At this point, the long-term implications of early NEDA remain largely unknown. We review current NEDA definitions, use in clinical trials, and its prospects for routine use as an actionable treatment target in clinical practice.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据